Suppr超能文献

六种 trkB 抗体的药理学特性揭示了一类新型的 BDNF 受体功能研究试剂。

Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

机构信息

Laboratory of Neurobiology & Molecular Pharmacology, Centre de Psychiatrie et Neurosciences, UMR-894 INSERM/Université Paris Descartes, 2Ter rue d'Alésia, Paris, France.

出版信息

Br J Pharmacol. 2011 Feb;162(4):947-60. doi: 10.1111/j.1476-5381.2010.01094.x.

Abstract

BACKGROUND AND PURPOSE

By interacting with trkB receptors, brain-derived neurotrophic factor (BDNF) triggers various signalling pathways responsible for neurone survival, differentiation and modulation of synaptic transmission. Numerous reports have implicated BDNF and trkB in the pathogenesis of various central nervous system affections and in cancer, thus representing trkB as a promising therapeutic target. In this study, we used an antibody-based approach to search for trkB-selective functional reagents.

EXPERIMENTAL APPROACH

Six commercially available polyclonal and monoclonal antibodies were tested on recombinant and native, human and rodent trkB receptors. Functional and pharmacological characterization was performed using a modified version of the KIRA-elisa method and radioligand binding studies. Western blot analyses and neurite outgrowth assays were carried out to determine the specificity and selectivity of antibody effects. The survival properties of one antibody were further assessed on cultured neurones in a serum-deprived paradigm.

KEY RESULTS

The functional trkB-selective antibodies showed distinct pharmacological profiles, ranging from partial agonists to antagonists, acting on trkB receptors through allosteric modulations. The same diversity of effects was observed on the mitogen-activated protein kinase signalling pathway downstream of trkB and on the subsequent neurite outgrowth. One antibody with partial agonist activity demonstrated cell survival properties by activating the Akt pathway. Finally, these antibodies were functionally validated as true trkB-selective ligands because they failed activating trkA or trkC, and contrary to BDNF, none of them bind to p75(NTR).

CONCLUSIONS AND IMPLICATIONS

These trkB-selective antibodies represent a novel class of pharmacological tools to explore the pathophysiological roles of trkB and its potential therapeutic relevance for the treatment of various disorders.

摘要

背景与目的

脑源性神经营养因子(BDNF)通过与 trkB 受体相互作用,触发各种信号通路,负责神经元的存活、分化和突触传递的调节。大量报道表明 BDNF 和 trkB 在各种中枢神经系统疾病和癌症的发病机制中起作用,因此 trkB 被认为是一个有前途的治疗靶点。在这项研究中,我们使用基于抗体的方法来寻找 trkB 选择性功能试剂。

实验方法

六种市售的多克隆和单克隆抗体在重组和天然的、人和啮齿动物的 trkB 受体上进行了测试。使用 KIRA-elisa 方法的修改版本和放射性配体结合研究进行功能和药理学特征分析。进行 Western blot 分析和神经突生长测定,以确定抗体作用的特异性和选择性。一种抗体的生存特性在血清剥夺范式下进一步在培养的神经元上进行评估。

主要结果

功能上选择性的 trkB 抗体显示出不同的药理学特征,从部分激动剂到拮抗剂,通过变构调节作用于 trkB 受体。在 trkB 下游的丝裂原活化蛋白激酶信号通路以及随后的神经突生长方面也观察到相同的多种效应。一种具有部分激动剂活性的抗体通过激活 Akt 通路显示出细胞生存特性。最后,这些抗体被功能上验证为真正的 trkB 选择性配体,因为它们不能激活 trkA 或 trkC,而且与 BDNF 不同,它们都不与 p75(NTR)结合。

结论和意义

这些 trkB 选择性抗体代表了一类新的药理学工具,可以探索 trkB 的病理生理作用及其在治疗各种疾病中的潜在治疗相关性。

相似文献

6
Neurotrophic effect of a novel TrkB agonist on retinal ganglion cells.新型 TrkB 激动剂对视网膜神经节细胞的神经营养作用。
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1747-54. doi: 10.1167/iovs.09-4450. Epub 2009 Oct 29.

引用本文的文献

2
Novel CAR-T cells targeting TRKB for the treatment of solid cancer.针对实体瘤的新型靶向 TRKB 的 CAR-T 细胞疗法。
Apoptosis. 2024 Dec;29(11-12):2183-2196. doi: 10.1007/s10495-024-01936-7. Epub 2024 Mar 18.

本文引用的文献

3
Guide to Receptors and Channels (GRAC), 4th Edition.《受体与通道指南》(第4版)
Br J Pharmacol. 2009 Nov;158 Suppl 1(Suppl 1):S1-254. doi: 10.1111/j.1476-5381.2009.00499.x.
5
Molecular signaling mechanisms underlying epileptogenesis.癫痫发生的分子信号传导机制。
Sci STKE. 2006 Oct 10;2006(356):re12. doi: 10.1126/stke.3562006re12.
9
Neurotrophins: mediators and modulators of pain.神经营养因子:疼痛的介质和调节因子
Annu Rev Neurosci. 2006;29:507-38. doi: 10.1146/annurev.neuro.29.051605.112929.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验